𝔖 Bobbio Scriptorium
✦   LIBER   ✦

746 NARLAPREVIR AND PEGINTERFERON ALFA-2B FOR 2 WEEKS IN CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS, FOLLOWED BY PEGINTERFERON ALFA-2B AND RIBAVIRIN FOR 24/48 WEEKS: FINAL RESULTS

✍ Scribed by J. de Bruijne; J.F. Bergmann; C.J. Weegink; R. Molenkamp; J. Schinkel; M.A. Treitel; E.A. Hughes; A. van Vliet; R.J. de Knegt; H.W. Reesink; H.L.A. Janssen

Book ID
117378830
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
69 KB
Volume
52
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Randomized trial of peginterferon alfa-2
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response
✍ Maria Buti; Yoav Lurie; Natalia G. Zakharova; Natalia P. Blokhina; Andrzej Horba πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 197 KB πŸ‘ 2 views

The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RBV) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatm